生技醫藥
NEW

2024莫德納台灣mRNA前瞻新創獎揭曉！ 安立璽榮、台大、清大、中興、研生生醫共享250萬獎金  
醫療科技
NEW

光鼎生技前10月歐洲市場年增34% 海外參展持續擴市占

政策法規
NEW

破解授權隱形成本！ 資策會科法所攜律師解析「稅務」眉角

GBI International
GBIHighlights

Brain Navi and JelloX are selected for the Mayo Clinic and ASU MedTech Accelerator program

2024-03-31/GlobalBio & Investment
#MedTechInnovationExcitingnews!CongratulationstoBrainNaviBiotechnologyCo.,Ltd.andJelloXBiotechInc.forbeingselectedfortheMayoClinicandASUMedTechAcceleratorprogram!MayoClinicandArizonaStateUniversity(AS...
GBI International
GBIHighlights

Dr. Sung-Jan Lin: Communication between internal stem cell niche and the external environment

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionOnMarch11th(Mon.),StanfordUniversityfromtheU.S.,KaohsiungMedicalUniversity,andAcademiaSinicawilljointlyhostthe2024Stanford-TaiwanSymposiumoniPSCandRegenerativeMedicine.Inthisevent,Dr...
GBI International
GBIHighlights

Dr. Yijuang Chern: Microglial Galectin-3 and Neuroinflammation...

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionOnMarch11th(Mon.),StanfordUniversityfromtheU.S.,KaohsiungMedicalUniversity,andAcademiaSinicawilljointlyhostthe2024Stanford-TaiwanSymposiumoniPSCandRegenerativeMedicine.Inthisevent,Dr...
GBI International
GBIHighlights

Dr. Ying-Chih Chang: Harnessing Biomimetic Materials to Induce Stemness in Rare Cells for...

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionOnMarch11th(Mon.),StanfordUniversityfromtheU.S.,KaohsiungMedicalUniversity,andAcademiaSinicawilljointlyhostthe2024Stanford-TaiwanSymposiumoniPSCandRegenerativeMedicine.????Inthiseven...
GBI International
GBIHighlights

Dr. Shihhwa Chiou: Application of iPSC-based Technology on Retinal Diseases

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionOnMarch11th(Mon.),StanfordUniversityfromtheU.S.,KaohsiungMedicalUniversity,andAcademiaSinicawilljointlyhostthe2024Stanford-TaiwanSymposiumoniPSCandRegenerativeMedicine.????Inthiseven...
GBI International
GBIHighlights

Dr. Jun-An Chen: Conducting the Neuronal Molecular Symphony

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionOnMarch11th(Mon.),StanfordUniversityfromtheU.S.,KaohsiungMedicalUniversity,andAcademiaSinicawilljointlyhostthe2024Stanford-TaiwanSymposiumoniPSCandRegenerativeMedicine.Inthisevent,Dr...
GBI International
GBIHighlights

Dr. Patrick Hsieh: Taiwan iPSC Bank for precision medicine and cell therapy

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionOnMarch11th(Mon.),StanfordUniversityfromtheU.S.,KaohsiungMedicalUniversity,andAcademiaSinicawilljointlyhostthe2024Stanford-TaiwanSymposiumoniPSCandRegenerativeMedicine.Inthisevent,Dr...
GBI International
GBIHighlights

Make a Wild Horse into a Pegasus! iPS Cells Research in Taiwan – List of Scientists!

2024-03-31/GlobalBio & Investment
#iPSCellRevolutionThe#iPSCellRevolutionsignifiestherevolutionarydiscoveryofinducedpluripotentstemcells(iPScells)byDr.ShinyaYamanaka(山中伸弥)in2006.Sincethen,scientistsworldwidehavebeenworkinghardtoexplor...
GBI International
GBIHighlights

Formosa Pharmaceuticals, Inc. has received FDA approval for their ophthalmic eye drops

2024-03-31/GlobalBio & Investment
#FDAApprovalExcitingnews!FormosaPharmaceuticals,Inc.(6838.TWO)hasreceivedFDAapprovalfortheirhashtag#ophthalmiceyedrops,APP13007,whichareusedtotreatpost-operativeinflammationandpainfollowingeyesurgery....
GBI International
GBIHighlights

Taiwan’s research and development of rare disease drugs has yielded great results!

2024-03-31/GlobalBio & Investment
#RareDiseaseBreakthroughsAmidstthepandemic,Taiwanesepharmaceuticalcompaniesdevelopingrarediseasedrugshavereportedpositiveresultsinclinicaltrials,leadingtoremarkablegrowthintheirstocks.Over30companiesi...
生技醫藥
新聞集錦 Keytruda CDMO

ADC需求增！英CDMO Abzena擴建美國基地；默沙東Keytruda獲歐盟批准聯合鉑類化療治非小細胞肺癌；藥華藥PV新藥申請巴西藥證

2024-03-29/編輯部
《臺灣》晟德轉投資香港賽生醫藥獲SilverPegasus以33.9%溢價全面收購 今(29)日，晟德(4123)轉投資香港公司賽生醫藥(6600.HK)與德福資本公告宣布，SilverPegasusInvestment擬以溢價33.9%的價格，即每股18.8港元(約總市值127億港元)，全面收購賽生在外流通股票，並計劃在撤銷賽生在聯合交易所的上市地位，達成私有化。 賽生近年來業績表現優異，202...
生技醫藥
505(b)(2) 止痛藥 新劑型新藥 骨關節炎

竟天兩大新藥臨床進度佳 啟動IPO規劃最快今年底送件

2024-03-29/記者 巫芝岳
今(29)日，竟天生物科技(6917)董事會通過去(2023)年財務報告。因旗下新藥尚處於研發與臨床試驗階段，學名藥銷售尚未顯現規模經濟，致使去年仍為虧損，每股虧損1.87元。正在臨床階段的APC101、APC201新藥進展順利，竟天將啟動IPO規劃，預計最快年底前送件申請上櫃。 竟天表示，目前緩解帶狀疱疹後神經痛噴霧新藥APC101、骨關節炎局部疼痛泡沫劑新藥APC201的臨床試驗進展順利，近期...

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：[email protected]
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務